What question did this study set out to answer?

To determine the protective effects and underlying molecular mechanisms of 1-deoxynojirimycin against diabetic liver injury in db/db mice.

February 19, 2025Endocrine Metabolic & Immune Disorders - Drug Targets

1-Deoxynojirimycin Ameliorates Diabetic Liver Injury by Regulating AMPK/SIRT1 and Oxidative Stress in db/db Mice

View Full Paper

Ask AI

Bookmark

Authors

YLYao Li YCYu CaoUnion Hospital YTYun-Yuan Tian

Discussion

Member takes

Implication

Preclinical study demonstrates that 1-deoxynojirimycin reduces steatosis and fibrosis in diabetic mice, indicating a protective mechanism via AMPK/SIRT1 signaling.

Key Points

To determine the protective effects and underlying molecular mechanisms of 1-deoxynojirimycin against diabetic liver injury in db/db mice.
Administered 1-deoxynojirimycin to db/db mice by oral gavage at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg daily for 8 weeks.
Assessed serum lipid parameters (TC, TG, LDL-C) and liver damage biomarkers (AST, ALT, TBiL), and analyzed liver histology using H&E, oil red, and Masson staining.
Measured hepatic reactive oxygen species and quantified protein expression related to fibrosis, antioxidant defense, and AMPK/SIRT1 pathways via Western blot.
1-deoxynojirimycin administration lowered body weight, liver coefficient, serum lipids (TC, TG, LDL-C), and liver injury markers (AST, ALT, TBiL).
Histological analysis revealed marked decreases in lipid deposition, ballooning degeneration, collagen accumulation, and expression of fibrosis markers α-SMA and Collagen I.
Treatment reduced hepatic reactive oxygen species while up-regulating SOD2, HO-1, NQO-1, p-AMPK, p-ACC, and SIRT1, and down-regulating SREBP-1 and SCD-1.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/6a003b552ff633f36577da45 https://doi.org/10.2174/0118715303327499250104221937

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates that 1-deoxynojirimycin reduces steatosis and fibrosis in diabetic mice, indicating a protective mechanism via AMPK/SIRT1 signaling.

1-Deoxynojirimycin Ameliorates Diabetic Liver Injury by Regulating AMPK/SIRT1 and Oxidative Stress in db/db Mice

Discussion

Member takes

Implication

Key Points

Cite This Study

1-Deoxynojirimycin Ameliorates Diabetic Liver Injury by Regulating AMPK/SIRT1 and Oxidative Stress in db/db Mice

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider